National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Daclizumab (Zinbryta®)

Daclizumab is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.

 

Rapid Review

Commenced Completed Outcome
26/09/2016 23/11/2016 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price

The HSE has approved reimbursement following confidential price negotiations.

7/03/2018 – The European Medicines Agency (EMA) has recommended the immediate suspension and recall of daclizumab.